One NEBA Health goal is help you control your healthcare. We’ve complied over 150 studies that may inform decisions you make about our dietary supplement offerings. To that end we provide articles with both positive and negative findings. For example, we include articles documenting studies where Omega-3s have no effect and articles where Omega-3s show […]
This study is the first to evaluate an assessment aid for attention- deficit/hyperactivity disorder (ADHD) according to both Class-I evidence stan- dards of American Academy of Neurology and De Novo requirements of US Food and Drug Administration. The assessment aid involves a method to inte- grate an electroencephalographic (EEG) biomarker, theta/beta ratio (TBR), with a […]
Investigators at the Research Institute Brainclinics, Nijmegen, Netherlands, conducted a meta-analysis on the Theta/Beta ratio (TBR) during Eyes Open from location Cz (the electrode halfway between the inion and the nasion) in the EEG of children/adolescents 6-18 years of age with and without ADHD. View Article (External Link)
We proposed a method to integrate an EEG biomarker together with a clinician’s ADHD evaluation. We evaluated whether this method would provide further information beyond the clinician’s initial evaluation and thereby improve accuracy. Download Poster PDF
Because ADHD symptoms overlap with other diagnoses, it may be difficult for clinicians to determine if ADHD is the primary cause, ADHD symptoms are secondary to other diagnoses, or ADHD is simply comorbid with other diagnoses. The NEBA System includes a method to integrate an EEG biomarker for ADHD (standardized theta/beta ratio) with a clinician’s […]
NEBA Health, LLC releases today key study results regarding the FDA approval of NEBA®, the first brain wave test to help clinicians assess ADHD in children and adolescents. Download PDF